先健科技(深圳)有限公司

先健科技公司(1302.HK)及其附属公司是全球领先的治疗心脑血管和周围血管疾病的微创介入医疗器械供应商，集研发、制造和销售于一体。于1999年成立先健科技（深圳）有限公司，并随后在荷兰、法国、斯洛伐克、俄罗斯、印度、香港、北京、上海、广州、深圳设立了多个子公司和销售办事处。2011年11月，先健科技公司于香港联合交易所成功上市。2012年10月，先健科技公司与美国美敦力公司建立战略合作关系，美敦力成为先健科技公司的战略股东，并成为先健科技公司第三代先心病封堵器等产品在西欧和中东指定国家的唯一代理商，随后双方扩大战略合作，共同致力于在中国推出本土生产的世界高品质的心脏起搏器，惠及更多患者。目前，先健科技公司具有自主知识产权的创新型产品畅销全球76个国家，拥有160多家经销商，广泛覆盖欧洲、南美洲、亚洲、非洲等地，是全球第二大及金砖四国第一大的先心病封堵器供应商，在全球先心病封堵器市场具有重大影响力。同时，先健科技公司亦凭借其领先的科研水平和硬件设施，承担了多项政府科研项目，是国家高新技术企业和***博士后科研工作站。Lifetech is the world`s leading supplier of minimally invasive interventional medical device for treatment of cardiovascular and peripheral vascular diseases and the Company is specialized in product R&D, manufacture and sales.Lifetech Scientific (Shenzhen) Co., Ltd. has been established in 1999, other subsidiaries and sales offices across the world have been set up afterwards. In November 2011, the Company was successfully listed in Hong Kong Stock Exchange. In October 2012, the Company reached strategic cooperation with Medtronic, the world top-notched medical device provider based in the US, and allowing Medtronic to become the strategic shareholder of the Company.As the world’s second largest (and the largest among BRIC countries) supplier of congenital heart occluder, Lifetech has significant influence on the global congenital heart occluder market. At present, the Company`s innovative products with self-owned intellectual property rights are well-marketed in 76 countries by more than 160 distributors. Meanwhile, the Company has undertaken various government research projects by virtue of its leading research capacity and facilities. The Company has also been granted the national high-tech enterprises and national post-doctoral research center in China.